Autonomix Medical shares surge 62.31% premarket after positive subgroup analysis shows durable quality-of-life improvements in advanced pancreatic cancer patients.

Autonomix Medical surged 62.31% in premarket trading following the release of positive post-hoc subgroup analysis results from its first-in-human trial of transvascular nerve ablation therapy for pancreatic cancer pain. The data demonstrated sustained, clinically meaningful improvements in quality of life, symptom burden, and functionality across disease stages, including late-stage patients with metastases, who showed 32.48-point symptom reductions at 4–6 weeks. These findings, exceeding EORTC thresholds, validated the therapy’s potential to address unmet needs in palliative care and informed plans for a 2026 U.S. multicenter trial. The CEO emphasized the real-world applicability of the results, while the data complemented prior reports of significant pain reduction and opioid-free outcomes. The surge reflected investor optimism about the therapy’s market potential and regulatory pathway, despite the small sample size and need for prospective validation.